Copyright Reports & Markets. All rights reserved.

Global Neoantigen Cancer Vaccine Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered: Ranking by Neoantigen Cancer Vaccine Revenue
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Neoantigen Cancer Vaccine Market Size Growth Rate by Type: 2020 VS 2026
      • 1.4.2 Personalized Vaccine
      • 1.4.3 Off-the-shelf Neovaccines
    • 1.5 Market by Application
      • 1.5.1 Global Neoantigen Cancer Vaccine Market Share by Application: 2020 VS 2026
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends by Regions

    • 2.1 Neoantigen Cancer Vaccine Market Perspective (2015-2026)
    • 2.2 Neoantigen Cancer Vaccine Growth Trends by Regions
      • 2.2.1 Neoantigen Cancer Vaccine Market Size by Regions: 2015 VS 2020 VS 2026
      • 2.2.2 Neoantigen Cancer Vaccine Historic Market Share by Regions (2015-2020)
      • 2.2.3 Neoantigen Cancer Vaccine Forecasted Market Size by Regions (2021-2026)
    • 2.3 Industry Trends and Growth Strategy
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis
      • 2.3.5 Neoantigen Cancer Vaccine Market Growth Strategy
      • 2.3.6 Primary Interviews with Key Neoantigen Cancer Vaccine Players (Opinion Leaders)

    3 Competition Landscape by Key Players

    • 3.1 Global Top Neoantigen Cancer Vaccine Players by Market Size
      • 3.1.1 Global Top Neoantigen Cancer Vaccine Players by Revenue (2015-2020)
      • 3.1.2 Global Neoantigen Cancer Vaccine Revenue Market Share by Players (2015-2020)
      • 3.1.3 Global Neoantigen Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 3.2 Global Neoantigen Cancer Vaccine Market Concentration Ratio
      • 3.2.1 Global Neoantigen Cancer Vaccine Market Concentration Ratio (CR5 and HHI)
      • 3.2.2 Global Top 10 and Top 5 Companies by Neoantigen Cancer Vaccine Revenue in 2019
    • 3.3 Neoantigen Cancer Vaccine Key Players Head office and Area Served
    • 3.4 Key Players Neoantigen Cancer Vaccine Product Solution and Service
    • 3.5 Date of Enter into Neoantigen Cancer Vaccine Market
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type (2015-2026)

    • 4.1 Global Neoantigen Cancer Vaccine Historic Market Size by Type (2015-2020)
    • 4.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Type (2021-2026)

    5 Neoantigen Cancer Vaccine Breakdown Data by Application (2015-2026)

    • 5.1 Global Neoantigen Cancer Vaccine Market Size by Application (2015-2020)
    • 5.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Application (2021-2026)

    6 North America

    • 6.1 North America Neoantigen Cancer Vaccine Market Size (2015-2020)
    • 6.2 Neoantigen Cancer Vaccine Key Players in North America (2019-2020)
    • 6.3 North America Neoantigen Cancer Vaccine Market Size by Type (2015-2020)
    • 6.4 North America Neoantigen Cancer Vaccine Market Size by Application (2015-2020)

    7 Europe

    • 7.1 Europe Neoantigen Cancer Vaccine Market Size (2015-2020)
    • 7.2 Neoantigen Cancer Vaccine Key Players in Europe (2019-2020)
    • 7.3 Europe Neoantigen Cancer Vaccine Market Size by Type (2015-2020)
    • 7.4 Europe Neoantigen Cancer Vaccine Market Size by Application (2015-2020)

    8 China

    • 8.1 China Neoantigen Cancer Vaccine Market Size (2015-2020)
    • 8.2 Neoantigen Cancer Vaccine Key Players in China (2019-2020)
    • 8.3 China Neoantigen Cancer Vaccine Market Size by Type (2015-2020)
    • 8.4 China Neoantigen Cancer Vaccine Market Size by Application (2015-2020)

    9 Japan

    • 9.1 Japan Neoantigen Cancer Vaccine Market Size (2015-2020)
    • 9.2 Neoantigen Cancer Vaccine Key Players in Japan (2019-2020)
    • 9.3 Japan Neoantigen Cancer Vaccine Market Size by Type (2015-2020)
    • 9.4 Japan Neoantigen Cancer Vaccine Market Size by Application (2015-2020)

    10 Southeast Asia

    • 10.1 Southeast Asia Neoantigen Cancer Vaccine Market Size (2015-2020)
    • 10.2 Neoantigen Cancer Vaccine Key Players in Southeast Asia (2019-2020)
    • 10.3 Southeast Asia Neoantigen Cancer Vaccine Market Size by Type (2015-2020)
    • 10.4 Southeast Asia Neoantigen Cancer Vaccine Market Size by Application (2015-2020)

    11 India

    • 11.1 India Neoantigen Cancer Vaccine Market Size (2015-2020)
    • 11.2 Neoantigen Cancer Vaccine Key Players in India (2019-2020)
    • 11.3 India Neoantigen Cancer Vaccine Market Size by Type (2015-2020)
    • 11.4 India Neoantigen Cancer Vaccine Market Size by Application (2015-2020)

    12 Central & South America

    • 12.1 Central & South America Neoantigen Cancer Vaccine Market Size (2015-2020)
    • 12.2 Neoantigen Cancer Vaccine Key Players in Central & South America (2019-2020)
    • 12.3 Central & South America Neoantigen Cancer Vaccine Market Size by Type (2015-2020)
    • 12.4 Central & South America Neoantigen Cancer Vaccine Market Size by Application (2015-2020)

    13 Key Players Profiles

    • 13.1 Roche
      • 13.1.1 Roche Company Details
      • 13.1.2 Roche Business Overview and Its Total Revenue
      • 13.1.3 Roche Neoantigen Cancer Vaccine Introduction
      • 13.1.4 Roche Revenue in Neoantigen Cancer Vaccine Business (2015-2020))
      • 13.1.5 Roche Recent Development
    • 13.2 Medimmune
      • 13.2.1 Medimmune Company Details
      • 13.2.2 Medimmune Business Overview and Its Total Revenue
      • 13.2.3 Medimmune Neoantigen Cancer Vaccine Introduction
      • 13.2.4 Medimmune Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
      • 13.2.5 Medimmune Recent Development
    • 13.3 Merck
      • 13.3.1 Merck Company Details
      • 13.3.2 Merck Business Overview and Its Total Revenue
      • 13.3.3 Merck Neoantigen Cancer Vaccine Introduction
      • 13.3.4 Merck Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
      • 13.3.5 Merck Recent Development
    • 13.4 Advaxis
      • 13.4.1 Advaxis Company Details
      • 13.4.2 Advaxis Business Overview and Its Total Revenue
      • 13.4.3 Advaxis Neoantigen Cancer Vaccine Introduction
      • 13.4.4 Advaxis Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
      • 13.4.5 Advaxis Recent Development
    • 13.5 Agenus
      • 13.5.1 Agenus Company Details
      • 13.5.2 Agenus Business Overview and Its Total Revenue
      • 13.5.3 Agenus Neoantigen Cancer Vaccine Introduction
      • 13.5.4 Agenus Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
      • 13.5.5 Agenus Recent Development
    • 13.6 Genocea
      • 13.6.1 Genocea Company Details
      • 13.6.2 Genocea Business Overview and Its Total Revenue
      • 13.6.3 Genocea Neoantigen Cancer Vaccine Introduction
      • 13.6.4 Genocea Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
      • 13.6.5 Genocea Recent Development
    • 13.7 Gritstone Oncology
      • 13.7.1 Gritstone Oncology Company Details
      • 13.7.2 Gritstone Oncology Business Overview and Its Total Revenue
      • 13.7.3 Gritstone Oncology Neoantigen Cancer Vaccine Introduction
      • 13.7.4 Gritstone Oncology Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
      • 13.7.5 Gritstone Oncology Recent Development
    • 13.8 Neon Therapeutics
      • 13.8.1 Neon Therapeutics Company Details
      • 13.8.2 Neon Therapeutics Business Overview and Its Total Revenue
      • 13.8.3 Neon Therapeutics Neoantigen Cancer Vaccine Introduction
      • 13.8.4 Neon Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
      • 13.8.5 Neon Therapeutics Recent Development
    • 13.9 Nouscom
      • 13.9.1 Nouscom Company Details
      • 13.9.2 Nouscom Business Overview and Its Total Revenue
      • 13.9.3 Nouscom Neoantigen Cancer Vaccine Introduction
      • 13.9.4 Nouscom Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
      • 13.9.5 Nouscom Recent Development
    • 13.10 OSE Immunotherapeutics
      • 13.10.1 OSE Immunotherapeutics Company Details
      • 13.10.2 OSE Immunotherapeutics Business Overview and Its Total Revenue
      • 13.10.3 OSE Immunotherapeutics Neoantigen Cancer Vaccine Introduction
      • 13.10.4 OSE Immunotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
      • 13.10.5 OSE Immunotherapeutics Recent Development
    • 13.11 Medigene
      • 10.11.1 Medigene Company Details
      • 10.11.2 Medigene Business Overview and Its Total Revenue
      • 10.11.3 Medigene Neoantigen Cancer Vaccine Introduction
      • 10.11.4 Medigene Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
      • 10.11.5 Medigene Recent Development
    • 13.12 Vaccibody
      • 10.12.1 Vaccibody Company Details
      • 10.12.2 Vaccibody Business Overview and Its Total Revenue
      • 10.12.3 Vaccibody Neoantigen Cancer Vaccine Introduction
      • 10.12.4 Vaccibody Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
      • 10.12.5 Vaccibody Recent Development
    • 13.13 Brightpath Biotherapeutics
      • 10.13.1 Brightpath Biotherapeutics Company Details
      • 10.13.2 Brightpath Biotherapeutics Business Overview and Its Total Revenue
      • 10.13.3 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Introduction
      • 10.13.4 Brightpath Biotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
      • 10.13.5 Brightpath Biotherapeutics Recent Development
    • 13.14 Geneos Therapeutics
      • 10.14.1 Geneos Therapeutics Company Details
      • 10.14.2 Geneos Therapeutics Business Overview and Its Total Revenue
      • 10.14.3 Geneos Therapeutics Neoantigen Cancer Vaccine Introduction
      • 10.14.4 Geneos Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2015-2020)
      • 10.14.5 Geneos Therapeutics Recent Development

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
        • 15.1.2 Data Source
      • 15.2 Disclaimer

      This report focuses on the global Neoantigen Cancer Vaccine status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Neoantigen Cancer Vaccine development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Roche
      Medimmune
      Merck
      Advaxis
      Agenus
      Genocea
      Gritstone Oncology
      Neon Therapeutics
      Nouscom
      OSE Immunotherapeutics
      Medigene
      Vaccibody
      Brightpath Biotherapeutics
      Geneos Therapeutics

      Market segment by Type, the product can be split into
      Personalized Vaccine
      Off-the-shelf Neovaccines
      Market segment by Application, split into
      Hospital
      Clinic
      Others

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Neoantigen Cancer Vaccine status, future forecast, growth opportunity, key market and key players.
      To present the Neoantigen Cancer Vaccine development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by type, market and key regions.

      In this study, the years considered to estimate the market size of Neoantigen Cancer Vaccine are as follows:
      History Year: 2015-2019
      Base Year: 2019
      Estimated Year: 2020
      Forecast Year 2020 to 2026
      For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now